{"id":"riociguat-adempas","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Hypotension"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Dyspepsia"},{"rate":"5-10","effect":"Dizziness"},{"rate":"2-5","effect":"Syncope"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Riociguat binds to and activates soluble guanylate cyclase (sGC) independent of nitric oxide availability, increasing intracellular cyclic GMP (cGMP) concentrations. This leads to smooth muscle relaxation in pulmonary and systemic vasculature, reducing pulmonary vascular resistance and improving hemodynamics in pulmonary hypertension. Unlike phosphodiesterase-5 inhibitors that prevent cGMP breakdown, riociguat directly stimulates cGMP production, making it effective even in conditions with impaired nitric oxide signaling.","oneSentence":"Riociguat is a soluble guanylate cyclase stimulator that directly activates the enzyme to increase cyclic GMP levels, promoting vasodilation and reducing pulmonary vascular resistance.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:17.317Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary hypertension (chronic thromboembolic pulmonary hypertension, CTEPH)"},{"name":"Pulmonary hypertension (WHO Group 1, pulmonary arterial hypertension)"}]},"trialDetails":[{"nctId":"NCT02562235","phase":"PHASE3","title":"Riociguat in Children With Pulmonary Arterial Hypertension (PAH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2015-10-29","conditions":"Hypertension, Pulmonary","enrollment":24},{"nctId":"NCT03409588","phase":"PHASE2","title":"Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2018-06-13","conditions":"Chronic Thromboembolic Disease (CTED), Exercise Intolerance Post PEA Surgery","enrollment":10},{"nctId":"NCT07374302","phase":"","title":"Riociguat in Triple Therapy for Pulmonary Arterial Hypertension in Real-World Practice","status":"NOT_YET_RECRUITING","sponsor":"Caio Júlio César dos Santos Fernandes","startDate":"2026-03-01","conditions":"Pulmonary Arterial Hypertension","enrollment":15},{"nctId":"NCT05339087","phase":"PHASE2","title":"Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH","status":"TERMINATED","sponsor":"Heidelberg University","startDate":"2022-10-24","conditions":"Pulmonary Vascular Disorder, Primary Pulmonary Hypertension, Systemic Sclerosis","enrollment":35},{"nctId":"NCT07356778","phase":"PHASE4","title":"A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy","status":"RECRUITING","sponsor":"Kazuya Hosokawa","startDate":"2025-10-07","conditions":"Eisenmenger Syndrome, Pulmonary Arterial Hypertension of Congenital Heart Disease","enrollment":36},{"nctId":"NCT05140525","phase":"PHASE3","title":"Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH","status":"RECRUITING","sponsor":"Dr Sudarshan Rajagopal","startDate":"2025-01-27","conditions":"CTEPH","enrollment":15},{"nctId":"NCT02759419","phase":"PHASE4","title":"A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-06-16","conditions":"Hypertension, Pulmonary","enrollment":18},{"nctId":"NCT04954742","phase":"PHASE4","title":"Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH","status":"TERMINATED","sponsor":"Heidelberg University","startDate":"2022-04-13","conditions":"Primary Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension","enrollment":30},{"nctId":"NCT01065454","phase":"PHASE2","title":"A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-04-14","conditions":"Hypertension, Pulmonary, Ventricular Dysfunction, Left","enrollment":202},{"nctId":"NCT01347216","phase":"","title":"COMPERA / COMPERA-KIDS","status":"RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2007-07-01","conditions":"Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH)","enrollment":14000},{"nctId":"NCT00694850","phase":"PHASE2","title":"Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-08-02","conditions":"Hypertension, Pulmonary","enrollment":22},{"nctId":"NCT04780932","phase":"PHASE2, PHASE3","title":"Initial Dual Oral Combination Therapy Versus Standard-of-care Initial Oral Monotherapy Prior to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-06-14","conditions":"Thromboembolic Pulmonary Hypertension, Chronic Disease, Inoperable Disease","enrollment":96},{"nctId":"NCT06715280","phase":"PHASE4","title":"Switching of Sildenafil to Riociguat in CTEPH Patients","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-07-25","conditions":"Chronic Thromboembolic Pulmonary Hypertension","enrollment":30},{"nctId":"NCT06922240","phase":"PHASE3","title":"Riociguat-Discontinue Effects on Right HEART in CTEPH (RED-HEART)","status":"RECRUITING","sponsor":"Suqiao Yang","startDate":"2025-03-21","conditions":"Chronic Thromboembolic Pulmonary Hypertension","enrollment":68},{"nctId":"NCT04211272","phase":"PHASE1","title":"A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants","status":"COMPLETED","sponsor":"Actelion","startDate":"2020-01-14","conditions":"Healthy","enrollment":47},{"nctId":"NCT04062565","phase":"PHASE3","title":"Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2019-03-25","conditions":"Pulmonary Arterial Hypertension","enrollment":20},{"nctId":"NCT04813926","phase":"","title":"A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-07-16","conditions":"Pulmonary Arterial Hypertension","enrollment":500},{"nctId":"NCT06753981","phase":"","title":"Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study","status":"RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2024-12-10","conditions":"Arterial Pulmonary Hypertension (PAH)","enrollment":48},{"nctId":"NCT05825417","phase":"PHASE4","title":"Pulmonary Hypertension: Intensification and Personalisation of Combination Rx","status":"RECRUITING","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2023-06-14","conditions":"Pulmonary Arterial Hypertension","enrollment":40},{"nctId":"NCT05750446","phase":"NA","title":"Effect of Riocigaut on Migraine Attack Induction in People With Migraine","status":"COMPLETED","sponsor":"Danish Headache Center","startDate":"2023-06-01","conditions":"Migraine Without Aura","enrollment":22},{"nctId":"NCT02117791","phase":"","title":"Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH )","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-07-16","conditions":"Hypertension, Pulmonary","enrollment":1298},{"nctId":"NCT02428985","phase":"","title":"Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-29","conditions":"Hypertension, Pulmonary","enrollment":882},{"nctId":"NCT05582811","phase":"NA","title":"Effect of Riocigaut on Cerebral Vasodilation and Headache Induction in Healthy Volunteers","status":"COMPLETED","sponsor":"Danish Headache Center","startDate":"2022-10-26","conditions":"Headache","enrollment":15},{"nctId":"NCT06180096","phase":"PHASE1","title":"Bioequivalence Study of Riociguat 2.5 mg Film Coated Tablets and Adempas (Riociguat) 2.5 mg Film Coated Tablets","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2023-03-07","conditions":"Pulmonary Arterial Hypertension","enrollment":36},{"nctId":"NCT00810693","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-12-17","conditions":"Pulmonary Hypertension","enrollment":445},{"nctId":"NCT00855465","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-02-23","conditions":"Pulmonary Hypertension","enrollment":262},{"nctId":"NCT02170025","phase":"PHASE2","title":"Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients","status":"TERMINATED","sponsor":"Bayer","startDate":"2014-09-30","conditions":"Cystic Fibrosis","enrollment":21},{"nctId":"NCT00910429","phase":"PHASE3","title":"BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-07-01","conditions":"Pulmonary Hypertension","enrollment":237},{"nctId":"NCT00863681","phase":"PHASE3","title":"BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-03-12","conditions":"Hypertension, Pulmonary","enrollment":396},{"nctId":"NCT05762146","phase":"PHASE2","title":"Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE","status":"UNKNOWN","sponsor":"Maastricht University","startDate":"2022-09-05","conditions":"Ischemic Stroke, Acute","enrollment":28},{"nctId":"NCT02633397","phase":"PHASE2","title":"A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases","status":"COMPLETED","sponsor":"Mark Gladwin","startDate":"2017-04-11","conditions":"Sickle Cell Disease","enrollment":130},{"nctId":"NCT03074539","phase":"NA","title":"Sleep-Disordered Breathing in Chronic Thromboembolic Pulmonary Hypertension","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2017-02-01","conditions":"Chronic Thromboembolic Pulmonary Hypertension, Sleep Disordered Breathing","enrollment":50},{"nctId":"NCT05478226","phase":"","title":"ADAMTSL4 in Idiopathic Pulmonary Hypertension and CTEPH","status":"COMPLETED","sponsor":"Wei Huang","startDate":"2018-07-01","conditions":"Pulmonary Hypertension","enrollment":67},{"nctId":"NCT02565030","phase":"","title":"Chronic Thrombo-embolic Pulmonary Hypertension: Classification and Long Term Outcome","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2015-02","conditions":"Chronic Thromboembolic Pulmonary Hypertension, Idiopathic Pulmonary Arterial Hypertension","enrollment":1200},{"nctId":"NCT04776499","phase":"PHASE1","title":"Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers","status":"COMPLETED","sponsor":"Maastricht University","startDate":"2021-03-18","conditions":"Drug Drug Interaction, Safety Issues","enrollment":8},{"nctId":"NCT03273257","phase":"PHASE2","title":"Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)","status":"TERMINATED","sponsor":"International CTEPH Association","startDate":"2018-08-17","conditions":"Chronic Thromboembolic Pulmonary Hypertension, CTEPH","enrollment":14},{"nctId":"NCT02891850","phase":"PHASE4","title":"Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-01-11","conditions":"Pulmonary Arterial Hypertension","enrollment":225},{"nctId":"NCT02634203","phase":"NA","title":"Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary Hypertension","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-01-19","conditions":"Chronic Thromboembolic Pulmonary Hypertension","enrollment":105},{"nctId":"NCT02744339","phase":"PHASE2","title":"Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2016-03","conditions":"Hypertension, Pulmonary, Heart Failure With Normal Ejection Fraction","enrollment":118},{"nctId":"NCT04600492","phase":"PHASE2","title":"THERAPY-HYBRID-BPA Trial","status":"UNKNOWN","sponsor":"National Hospital Organization Okayama Medical Center","startDate":"2020-10-16","conditions":"Hypertension, Pulmonary","enrollment":72},{"nctId":"NCT04366622","phase":"PHASE1","title":"Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-04-14","conditions":"Clinical Pharmacology","enrollment":32},{"nctId":"NCT04364464","phase":"PHASE1","title":"Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-02-19","conditions":"Clinical Pharmacology","enrollment":40},{"nctId":"NCT03809156","phase":"PHASE4","title":"Upfront Combination Pulmonary Arterial Hypertension Therapy","status":"UNKNOWN","sponsor":"University of Calgary","startDate":"2016-04-26","conditions":"Pulmonary Hypertension","enrollment":20},{"nctId":"NCT02283762","phase":"PHASE2","title":"Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-01-15","conditions":"Scleroderma, Systemic","enrollment":121},{"nctId":"NCT02915835","phase":"PHASE2","title":"Riociguat in Scleroderma Associated Digital Ulcers","status":"COMPLETED","sponsor":"Dinesh Khanna, MD, MS","startDate":"2016-09","conditions":"Scleroderma, Digital Ulcers","enrollment":17},{"nctId":"NCT02092818","phase":"","title":"EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-05-31","conditions":"Hypertension, Pulmonary","enrollment":1316},{"nctId":"NCT02007629","phase":"PHASE3","title":"Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-02-18","conditions":"Hypertension, Pulmonary","enrollment":61},{"nctId":"NCT02094001","phase":"PHASE2","title":"Pilot Study to Evaluate Right Ventricular Function With Riociguat in CTEPH","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2014-05","conditions":"Chronic Thromboembolic Pulmonary Hypertension","enrollment":6},{"nctId":"NCT03389321","phase":"PHASE1","title":"Clinical Study to Investigate Effect of Macitentan on Riociguat Pharmacokinetics","status":"COMPLETED","sponsor":"Actelion","startDate":"2018-01-09","conditions":"Healthy Subjects","enrollment":20},{"nctId":"NCT02556268","phase":"PHASE1","title":"Interaction With HIV Antiretroviral Agents","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-23","conditions":"HIV-DDI","enrollment":40},{"nctId":"NCT02138825","phase":"PHASE2","title":"Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)","status":"TERMINATED","sponsor":"Bayer","startDate":"2014-06-04","conditions":"Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary","enrollment":147},{"nctId":"NCT02191137","phase":"PHASE4","title":"Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-09-23","conditions":"Hypertension, Pulmonary","enrollment":75},{"nctId":"NCT02545465","phase":"","title":"A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-09-15","conditions":"Hypertension, Pulmonary","enrollment":125},{"nctId":"NCT02024386","phase":"PHASE4","title":"Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude","status":"COMPLETED","sponsor":"Richard Moon","startDate":"2014-01","conditions":"Hypertension, Pulmonary, Altitude Sickness","enrollment":28},{"nctId":"NCT00640315","phase":"PHASE1","title":"Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-08","conditions":"Hypertension, Pulmonary, Pulmonary Disease, Chronic Obstructive","enrollment":23},{"nctId":"NCT01179334","phase":"PHASE2","title":"Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-08","conditions":"Pulmonary Hypertension","enrollment":18},{"nctId":"NCT02159313","phase":"PHASE1","title":"Relative Bioavailability Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-06","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT01266265","phase":"","title":"Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies","status":"COMPLETED","sponsor":"United Therapeutics","startDate":"2010-12","conditions":"Pulmonary Arterial Hypertension","enrollment":1333},{"nctId":"NCT00855660","phase":"PHASE1","title":"Effect of Riociguat on Bone Metabolism","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-03","conditions":"Pharmacology, Clinical","enrollment":17},{"nctId":"NCT01784562","phase":"","title":"Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)","status":"NO_LONGER_AVAILABLE","sponsor":"Bayer","startDate":"","conditions":"Hypertension, Pulmonary","enrollment":""},{"nctId":"NCT00680654","phase":"PHASE1","title":"Interaction Study in Patients With Pulmonary Hypertension and Stable Treatment of Sildenafil 20 mg TID","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-10","conditions":"Hypertension, Pulmonary","enrollment":7},{"nctId":"NCT02625558","phase":"PHASE4","title":"Riociguat for Sarcoidosis Associated Pulmonary Hypertension","status":"UNKNOWN","sponsor":"University of Cincinnati","startDate":"2015-04","conditions":"Sarcoidosis","enrollment":60},{"nctId":"NCT00454558","phase":"PHASE2","title":"An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-01","conditions":"Hypertension, Pulmonary","enrollment":75},{"nctId":"NCT02159326","phase":"PHASE1","title":"Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-06","conditions":"Drug Interactions","enrollment":31},{"nctId":"NCT01489488","phase":"PHASE1","title":"Relative Bioavailability and Food Effect Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-01","conditions":"Pharmacology, Clinical","enrollment":32},{"nctId":"NCT01172756","phase":"PHASE2","title":"A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction","status":"TERMINATED","sponsor":"Bayer","startDate":"2010-07","conditions":"Hypertension, Pulmonary, Ventricular Dysfunction, Left","enrollment":39},{"nctId":"NCT01926847","phase":"PHASE2","title":"Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-10","conditions":"Raynaud Disease","enrollment":23},{"nctId":"NCT01065051","phase":"PHASE2","title":"Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics","status":"TERMINATED","sponsor":"Bayer","startDate":"2010-11","conditions":"Hypertension, Pulmonary, Ventricular Dysfunction, Left","enrollment":1},{"nctId":"NCT01165931","phase":"PHASE2","title":"Coronary Vasomotor Response After Riociguat Exposure","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2012-05","conditions":"Coronary Artery Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Riociguat (Adempas)","genericName":"Riociguat (Adempas)","companyName":"Chinese University of Hong Kong","companyId":"chinese-university-of-hong-kong","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Riociguat, also known as Adempas, is a small molecule that acts as a positive allosteric modulator of soluble guanylate cyclase. It is used to treat conditions such as pulmonary arterial hypertension and idiopathic interstitial pneumonias with hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}